Skip to main navigation

>> Site Menu

Our Company
Our Science
Our Products
Join Us
INVESTORS & MEDIA

Kodiak Sciences

>> Site Menu

Our Company
Our Science
Our Products
Join Us
INVESTORS & MEDIA

News Releases

> News - Sub Nav

Press Releases

News Releases

February 13, 2021

Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

Additional Formats

PDF Version

February 2, 2021

Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

Additional Formats

PDF Version

January 5, 2021

Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference

Additional Formats

PDF Version

November 20, 2020

Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Additional Formats

PDF Version

November 17, 2020

Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock

Additional Formats

PDF Version

November 16, 2020

Kodiak Sciences Announces Proposed Offering of Common Stock

Additional Formats

PDF Version

November 16, 2020

Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

Additional Formats

PDF Version

November 12, 2020

Kodiak Sciences to Present at Upcoming Conferences

Additional Formats

PDF Version

November 11, 2020

Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting

Additional Formats

PDF Version

November 9, 2020

Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Next page
Last page

Displaying 1 - 10 of 69

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

KODIAK SCIENCES INC.

1200 Page Mill Road
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter

Copyright © 2021 Kodiak Sciences Inc.